Menu
Recruiting NCT04101968

The GBA Multimodal Study in Parkinson's Disease

— Observational Parkinson Disease GBA Gene Mutation Gaucher Disease

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: PET scan, neuroQWERTY.
Who it may be relevant to
Registry conditions: Parkinson Disease, GBA Gene Mutation, Gaucher Disease. Basic parameters: 18 years — 80 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States, Canada
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

Multimodal Molecular Imaging and Biometric Analysis in GBA-PD and Asymptomatic GBA-mutation Carriers

Overview

This study plans to analyze the molecular and clinical mechanisms of the relationship between the GBA mutations and Parkinson's disease. This will be assessed through the use of advanced neuroimaging techniques called PET (positron emission tomography) to study the accumulation of the tau protein and the dysfunction of acetylcholine and dopamine in the brain of people with a mutation in the GBA gene, with and without Parkinson's disease. The ingestigators will also use a technology-based assessment to study the typing patterns as possible biomarkers of early motor dysfunctions.

Detailed description

Study Rationale: People who have a mutation in the GBA gene have a higher risk of developing Parkinson's disease (PD) and, if they have PD, are more likely to have cognitive decline and dementia. Cognitive problems in people with PD is related to dysfunction of the brain chemical acetylcholine and likely to the accumulation of the tau protein in the brain. Another observation in previous studies is that analyzing the patterns of typing into a computer can help differentiate healthy people from people with PD.

Hypothesis: The investigators hypothesize that people with GBA-related PD will have higher acetylcholine dysfunction and tau accumulation compared with non-GBA patients, and that these changes may start in the asymptomatic phase (i.e., people with the mutation but without symptoms of PD). The investigators also believe that the investigators will be able to detect subjects with higher degree of dopamine loss just by analyzing the way they type into a computer.

Study Design: The investigators will recruit 25 subjects with a GBA mutation (10 subjects with PD and 15 asymptomatic carriers). All the participants will have a clinical evaluation and a typing session, and subsequently will undergo a brain MRI and three PET scans with a tau tracer, an acetylcholine tracer, and a dopaminergic tracer. A blood sample will also be taken for the analysis of GCase (the enzyme related to the GBA mutation).

Impact on Diagnosis/Treatment of Parkinson's Disease: The results will help understand the changes that take place in the brain of people with GBA-related Parkinson's disease, and hopefully will shed light also on the pathophysiology of non-GBA-related Parkinson's, as well as on the molecular correlates of cognitive decline, especially in its early stage. The typing data along with dopaminergic imaging will clarify the possible role of using typing patterns to identify subjects with early stage Parkinson's disease.

Next Steps for Development: The findings of this study may help identify biomarkers for cognitive decline in early Parkinson's disease, with a potential role in clinical trials. Also, if the hypothesis on the typing is confirmed, this approach may be studied in larger cohorts for early diagnosis of Parkinson's in other at-risk populations.

Interventions

  • Diagnostic test PET scan
    3 PET scans to analyze the dopamine metabolism, acetylcholine and tau protein deposition in the brain.
  • Diagnostic test neuroQWERTY
    Analysis of free-text typing in a computer and/or a touch-screen device.

Primary outcome measures

  • Acetylcholinesterase activity [Time frame: baseline]
  • Tau protein deposition [Time frame: baseline]
  • Dopaminergic denervation [Time frame: baseline]
  • neuroQWERTY index [Time frame: baseline]

Eligibility criteria

Inclusion criteria

  • heterozygous for a pathogenic GBA mutation (e.g., p.L444P, p.N370S) or polymorphism;
  • age 18 to 80 years.

Exclusion criteria

  • co-occurrence of other neurological disorders;
  • implants that contraindicate the MRI scanning (e.g. cardiac pacemaker, ferromagnetic implants or devices);
  • severe claustrophobia;
  • intolerance to antiparkinsonian drug withdrawal (for GBA-PD subjects);
  • ongoing treatment with cholinergic drugs

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Cohort

Study locations

United States · 2 centers
  • Oregon Health & Science University — Portland
  • University of Washington — Seattle
Canada · 1 center
  • Pacific Parkinson's Research Centre | University of British Columbia — Vancouver

Identifiers

NCT: NCT04101968 · 16451

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗